COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s inosine/cn
L1 1 INOSINE/CN

=> d L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 58-63-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Inosine (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1,9-Dihydro-9-β-D-ribofuranosyl-6H-purin-6-one
CN 6H-Purin-6-one, 1,9-dihydro-9-β-D-ribofuranosyl-
CN 9-β-D-Ribofuranosylhypoxanthine
CN Atorel
CN HXR
CN Hypoxanthine 9-β-D-ribofuranoside
CN Hypoxanthine ribonucleoside
CN Hypoxanthine riboside
CN Hypoxanthine, 9-β-D-ribofuranosyl-
CN Hypoxanthosine
CN Ino
CN Inosie
CN NSC 20262
CN Oxiamin
CN Panholic-L
CN Ribonosine
CN Selfer
CN Trophicardyl
FS STEREOSEARCH
DR 691344-25-9, 740029-83-8, 12712-98-0, 132953-54-9, 4181-51-5, 28861-88-3,
292853-81-7
MF C10 H12 N4 O5
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,
CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB,
IFIPAT, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
NAPRALERT, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6030 REFERENCES IN FILE CA (1907 TO DATE)
191 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6040 REFERENCES IN FILE CAPLUS (1907 TO DATE)
86 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s arginine/cn
L2 2 ARGININE/CN

=> d L2 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7200-25-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Arginine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Arginine, DL- (8CI)
CN DL-Arginine
OTHER NAMES:
CN (±)-Arginine
FS 3D CONCORD
MF C6 H14 N4 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DETHERM*, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, NAPRALERT, PIRA, PROMT, TOXCENTER, TULSA, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

360 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
360 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 74-79-3 REGISTRY
ED Entered STN: 16 Nov 1984

CN L-Arginine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Arginine, L- (8CI)
OTHER NAMES:
CN (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
CN Arginine
CN L-(+)-Arginine
CN L-α-Amino-δ-guanidinovaleric acid
CN L-Arg
CN L-Norvaline, 5-[(aminoiminomethyl)amino]-
CN L-Ornithine, N5-(aminoiminomethyl)-
CN NSC 206269
CN Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-
FS STEREOSEARCH
DR 667422-95-9, 7004-12-8, 142-49-4
MF C6 H14 N4 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PATDPASPC, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

44093 REFERENCES IN FILE CA (1907 TO DATE)
1275 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
44173 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> exp inosine
E1          269     INOSINATE/BI
E2          344     INOSINATO/BI
E3         5157 --> INOSINE/BI
E4            1     INOSINEDI/BI
E5            1     INOSINEDICARBOX/BI
E6            1     INOSINEDICARBOXALDEHYDE/BI
E7            3     INOSINEMONO/BI
E8            3     INOSINEMONOPHOSPH/BI
E9            3     INOSINEMONOPHOSPHATE/BI
E10           1     INOSINEN/BI
E11           2     INOSINESIDE/BI
E12         999     INOSINIC/BI

=> exp inosine/cn
E1            1     INOSINATE NUCLEOSIDASE/CN
E2            1     INOSINATE PYROPHOSPHORYLASE/CN
E3            1 --> INOSINE/CN
E4            1     INOSINE (5'-), 5'-(PENTAHYDROGEN TETRAPHOSPHATE)/CN
```

```
E5            1      INOSINE 2',3',5'-TRINITRATE/CN
E6            1      INOSINE 2',5'-DIPHOSPHATE/CN
E7            1      INOSINE 2'-MONOPHOSPHATE/CN
E8            1      INOSINE 3',5'-CYCLIC MONOPHOSPHATE/CN
E9            1      INOSINE 3',5'-DIPHOSPHATE/CN
E10           1      INOSINE 3',5'-DIPHOSPHATE, 5'-ANHYDRIDE WITH H2SO4/CN
E11           1      INOSINE 3',5'-MONOPHOSPHATE/CN
E12           1      INOSINE 3'-(HEXAHYDROGEN PENTAPHOSPHATE), 3'.FWDARW.5'-ESTER
                      WITH 2',3'-O-(1-ETHOXY-2-(((PHENYLMETHOXY)CARBONYL)AMINO)PR
                     OPYLIDENE)INOSINE/CN

=> sel L1
E1 THROUGH E27 ASSIGNED

=> sel L2
E28 THROUGH E44 ASSIGNED

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     17.09      17.30

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:23:09 ON 12 JUL 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E1-E27) and (E28-E44)
          2   FILE ADISCTI
          5   FILE AGRICOLA
          5   FILE ANABSTR
   5 FILES SEARCHED...
         29   FILE AQUASCI
          3   FILE BIOENG
         88   FILE BIOSIS
  10 FILES SEARCHED...
         17   FILE BIOTECHABS
         17   FILE BIOTECHDS
         24   FILE BIOTECHNO
  13 FILES SEARCHED...
         20   FILE CABA
        396   FILE CAPLUS
          2   FILE CEABA-VTB
          2   FILE CROPU
          2   FILE DDFB
  21 FILES SEARCHED...
          9   FILE DDFU
         39   FILE DGENE
  23 FILES SEARCHED...
          8   FILE DISSABS
          2   FILE DRUGB
          5   FILE DRUGMONOG2
         10   FILE DRUGU
         84   FILE EMBASE
         34   FILE ESBIOBASE
  30 FILES SEARCHED...
          1   FILE FROSTI
         30   FILE FSTA
```

```
       308   FILE GENBANK
  35 FILES SEARCHED...
        63   FILE IFIPAT
        11   FILE JICST-EPLUS
        26   FILE LIFESCI
        82   FILE MEDLINE
  45 FILES SEARCHED...
        11   FILE OCEAN
        23   FILE PASCAL
  48 FILES SEARCHED...
         1   FILE PHIN
         4   FILE PROMT
         1   FILE RDISCLOSURE
  57 FILES SEARCHED...
        71   FILE SCISEARCH
        81   FILE TOXCENTER
      7417   FILE USPATFULL
       659   FILE USPAT2
  62 FILES SEARCHED...
        54   FILE WPIDS
  66 FILES SEARCHED...
        54   FILE WPINDEX
  68 FILES SEARCHED...
         2   FILE DPCI
       527   FILE EPFULL
  73 FILES SEARCHED...
        93   FILE FRFULL
  75 FILES SEARCHED...
        53   FILE GBFULL
         7   FILE INPADOC
         2   FILE JAPIO
  79 FILES SEARCHED...
  84 FILES SEARCHED...
         3   FILE PATDPAFULL
  85 FILES SEARCHED...
      6553   FILE PCTFULL
  87 FILES SEARCHED...
         1   FILE PIRA

  49 FILES HAVE ONE OR MORE ANSWERS,    92 FILES SEARCHED IN STNINDEX

L3    QUE ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI OR "HYPOXANT
          HINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-D-RIBOFURANOSIDE"/BI OR "H
          YPOXANTHINE, 9-B-D-RIBOFURANOSYL-"/BI OR HYPOXANTHOSINE/BI OR INO
          /BI OR INOSIE/BI OR INOSINE/BI OR "NSC 20262"/BI OR OXIAMIN/BI OR PANH
          OLIC-L/BI OR RIBONOSINE/BI OR SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIH
          YDRO-9-B-D-RIBOFURANOSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 1
          32953-54-9/BI OR 28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58
          -63-9/BI OR "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI
           OR 691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOXA
          NTHINE/BI)) AND ((ARGININE/BI OR "(±)-ARGININE"/BI OR "(S)-2-AMINO-
          5-((AMINOIMINOMETHYL)AMINO)PENTANOIC ACID"/BI OR DL-ARGININE/BI OR "L-
          A-AMINO-Δ-GUANIDINOVALERIC ACID"/BI OR "L-(+)-ARGININE"/BI
           OR L-ARG/BI OR L-ARGININE/BI OR "L-NORVALINE, 5-((AMINOIMINOMETHYL)AM
          INO)-"/BI OR "L-ORNITHINE, N5-(AMINOIMINOMETHYL)-"/BI OR "NSC 206269"/
          BI OR "PENTANOIC ACID, 2-AMINO-5-((AMINOIMINOMETHYL)AMINO)-, (S)-"/BI
          OR 142-49-4/BI OR 667422-95-9/BI OR 7004-12-8/BI OR 7200-25-1/BI OR 74
          -79-3/BI))

=> file file bioses embase medline uspatfull pecfull epfull caplus
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

```
ENTER A FILE NAME OR (IGNORE):ignore
'BIOSES' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):biosis
'PECFULL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    14.03      31.33

FILE 'BIOSIS' ENTERED AT 13:36:40 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:36:40 ON 12 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:36:40 ON 12 JUL 2006

FILE 'USPATFULL' ENTERED AT 13:36:40 ON 12 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:36:40 ON 12 JUL 2006
COPYRIGHT (C) 2006 Univentio

FILE 'EPFULL' ENTERED AT 13:36:40 ON 12 JUL 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'CAPLUS' ENTERED AT 13:36:40 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (E1-E27) and (E28-E44)
   2 FILES SEARCHED...
   4 FILES SEARCHED...
   5 FILES SEARCHED...
   6 FILES SEARCHED...
L4       15147 ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI OR
               "HYPOXANTHINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-D-RIBOFURAN
              OSIDE"/BI OR "HYPOXANTHINE, 9-B-D-RIBOFURANOSYL-"/BI OR
              HYPOXANTHOSINE/BI OR INO/BI OR INOSIE/BI OR INOSINE/BI OR "NSC
              20262"/BI OR OXIAMIN/BI OR PANHOLIC-L/BI OR RIBONOSINE/BI OR
              SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIHYDRO-9-B-D-RIBOFURAN
              OSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 132953-54-9/BI OR
              28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58-63-9/BI OR
              "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR
              691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOX
              ANTHINE/BI)) AND ((ARGININE/BI OR "(±)-ARGININE"/BI OR "(S)-2-
              AMINO-5-((AMINOIMINOMETHYL)AMINO)PENTANOIC ACID"/BI OR DL-ARGININ
              E/BI OR "L-A-AMINO-Δ-GUANIDINOVALERIC ACID"/BI OR
              "L-(+)-ARGININE"/BI OR L-ARG/BI OR L-ARGININE/BI OR "L-NORVALINE,
               5-((AMINOIMINOMETHYL)AMINO)-"/BI OR "L-ORNITHINE, N5-(AMINOIMINO
              METHYL)-"/BI OR "NSC 206269"/BI OR "PE

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   222.45     253.78
```

```
FILE 'REGISTRY' ENTERED AT 13:38:34 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 JUL 2006  HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES:  11 JUL 2006  HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> exp arginine/cn
E1            1     ARGININANILIDE, NA,NΩ,NΩ-TRIS(PHENYLCARBAM
                    OYL)-, L-/CN
E2            1     ARGININANILIDE, N2-BENZOYL-/CN
E3            2 --> ARGININE/CN
E4            1     ARGININE B-NAPHTHYLAMIDE/CN
E5            1     ARGININE 2,2,2-TRICHLOROETHYL ESTER/CN
E6            1     ARGININE 2,3-AMINOMUTASE/CN
E7            1     ARGININE 2,3-AMINOMUTASE (STREPTOMYCES GRISEOCHROMOGENES GEN
                    E BLSG)/CN
E8            1     ARGININE 2-MONOOXYGENASE/CN
E9            1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN
E10           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN
E11           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI STRAIN O157:H7 GENE ECS0943)/CN
E12           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI STRAIN O157:H7 GENE ECS0946)/CN

=> exp arginine inosinate/cn
E1            1     ARGININE HYDROXAMATE/CN
E2            1     ARGININE HYDROXAMATE RESISTANCE PROTEIN (CORYNEBACTERIUM GLU
                    TAMICUM STRAIN ATCC_13032 CLONE RXA02159)/CN
E3            0 --> ARGININE INOSINATE/CN
E4            1     ARGININE KINASE/CN
E5            1     ARGININE KINASE (APIS MELLIFERA GENE ARGK ISOENZYME C REDUCE
                    D)/CN
E6            1     ARGININE KINASE (BACILLUS CEREUS STRAIN ATCC 14579 GENE BC01
                    01)/CN
E7            1     ARGININE KINASE (BATILLUS CORNUTUS)/CN
E8            1     ARGININE KINASE (CALLINECTES SAPIDUS GILL)/CN
E9            1     ARGININE KINASE (CARCINUS MAENAS GILL GENE AK)/CN
E10           1     ARGININE KINASE (CHLAMYDIA PNEUMONIAE GENE KARG)/CN
E11           1     ARGININE KINASE (CHLAMYDIA PNEUMONIAE STRAIN J138 GENE KARG)
                    /CN
E12           1     ARGININE KINASE (CHLAMYDIA TRACHOMATIS STRAIN A/HAR-13 GENE
                    KARG)/CN
```

```
=> file file bioses embase medline uspatfull pecfull epfull caplus
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'BIOSES' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):biosis
'PECFULL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.44     254.22

FILE 'BIOSIS' ENTERED AT 13:39:17 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:39:17 ON 12 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:39:17 ON 12 JUL 2006

FILE 'USPATFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
COPYRIGHT (C) 2006 Univentio

FILE 'EPFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'CAPLUS' ENTERED AT 13:39:17 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l4 and solubility
L5        9456 L4 AND SOLUBILITY

=> s l5 and agrinine
L6           5 L5 AND AGRININE

=> s l5 and (arginine(w)inosinate)
L7           0 L5 AND (ARGININE(W) INOSINATE)

=> s l5 and (inosine(w)arginate)
L8           0 L5 AND (INOSINE(W) ARGINATE)

=> s l5 and salt
L9        8073 L5 AND SALT

=> s l( not py>2000
MISSING OPERATOR 'L( NOT'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> s l5 not py>2000
L10       1830 L5 NOT PY>2000

=> d L10 1-10 ti

L10  ANSWER 1 OF 1830  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   CHANGES IN NITROGEN COMPOUNDS OF FERMENTED SAUSAGE DURING RIPENING WITH
     LACTOBACILLUS-PLANTARUM.

L10  ANSWER 2 OF 1830  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY
     NUCLEOTIDES AND THEIR COMPONENTS.

L10  ANSWER 3 OF 1830  USPATFULL on STN
TI     Glutathione-S-conjugate transport in plants

L10  ANSWER 4 OF 1830  USPATFULL on STN
TI     PGC-1, a novel brown fat PPARγ coactivator

L10  ANSWER 5 OF 1830  USPATFULL on STN
TI     Telomerase catalytic subunit

L10  ANSWER 6 OF 1830  USPATFULL on STN
TI     Protein phosphatase-related molecules

L10  ANSWER 7 OF 1830  USPATFULL on STN
TI     Tao protein kinases and methods of use therefor

L10  ANSWER 8 OF 1830  USPATFULL on STN
TI     Vesicle transport protein

L10  ANSWER 9 OF 1830  USPATFULL on STN
TI     Metal-regulated transporters and uses therefor

L10  ANSWER 10 OF 1830  USPATFULL on STN
TI     Human pinin splice variant


=> s arginine/ti
L11       57015 ARGININE/TI

=> d L11 1-10 ti

L11  ANSWER 1 OF 57015  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   Cachectic tumor (MAC16) induces poor post-operative response with
     arginine deficiency.

L11  ANSWER 2 OF 57015  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   The effects of L-arginine on the cardiac function of advanced
     stage of myocardial reperfusion of rats in vivo.

L11  ANSWER 3 OF 57015  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   Increasing NO bioavailability though L-arginine supplementation
     or arginase inhibition augments reflex cutaneous vasodilation in aged
     skin.

L11  ANSWER 4 OF 57015  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on
     STN
TI   Chronic administration of NG-nitro-L-arginine methyl ester
     (L-NAME) on endothelium-dependent relaxation of porcine brachial and
```

femoral arteries.

L11 ANSWER 5 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Arginine therapy in transgenic-knockout sickle mice improves vascular reactivity by decreasing hemolysis and oxidative stress.

L11 ANSWER 6 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Critical functional role of arginine 75 in connexin 26 gap-junction channels and hemichannels.

L11 ANSWER 7 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Oral L-arginine supplementation increases VEGF in exhaled breath condensate (EBC) but not serum during acute ascent to 4383 m.

L11 ANSWER 8 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Arginine 466 in human Organic Anion Transporter 1 confers chloride sensitivity.

L11 ANSWER 9 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Fluoxetine inhibits arginine vasopressin (AVP)-stimulated water permeability in rat inner medullary collecting duct (IMCD) via alpha-2 mechanism.

L11 ANSWER 10 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI The immuno-modulatory effects of ornitine alpha-ketoglutarate, arginine, and glutamine in postoperative rats with parenteral nutrition.

=> s arginine/ti and inosine/ti
L12 12 ARGININE/TI AND INOSINE/TI

=> d L12 1-12 ti

L12 ANSWER 1 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and arginine 393.

L12 ANSWER 2 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.

L12 ANSWER 3 OF 12 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani: The role of conserved residues, aspartate 389 and arginine 393.

L12 ANSWER 4 OF 12 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Thermodynamic and kinetic parameters of oligonucleotide - oligopeptide interactions. Specificity of arginine inosine association.

L12 ANSWER 5 OF 12 MEDLINE on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and

arginine 393.

L12 ANSWER 6 OF 12 MEDLINE on STN
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.

L12 ANSWER 7 OF 12 USPATFULL on STN
TI Inosine L-Arginine salt and uses thereof

L12 ANSWER 8 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L12 ANSWER 9 OF 12 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN INOSINIE/L−ARGININE SALT AND USE THEREOF.
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION.

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Functional Analysis of an Inosine-Guanosine Transporter from Leishmania donovani: The Role of Conserved Residues, Aspartate 389 and Arginine 393

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Thermodynamic and kinetic parameters of oligonucleotide-oligopeptide interactions. Specificity of arginine.cntdot.inosine association

=> dup rem L12
PROCESSING COMPLETED FOR L12
L13 5 DUP REM L12 (7 DUPLICATES REMOVED)

=> d l13 1-7 ti

L13 ANSWER 1 OF 5 USPATFULL on STN
TI Inosine L-Arginine salt and uses thereof

L13 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN DUPLICATE DUPLICATE 1
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter

L13 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 2
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and arginine 393.

L13 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 3
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.

=> d L13 1 2 3 5 ti abs bib

L13 ANSWER 1 OF 5 USPATFULL on STN
TI Inosine L-Arginine salt and uses thereof
AB The present invention discloses an inosine. L-arginine salt, compositions containing the salt, and methods of using the salt and said compositions for cell activation and/or plant growth promotion. The salt can be stored and transported as a solid and dissolves quickly and efficiently when needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:247954 USPATFULL
TI Inosine L-Arginine salt and uses thereof
IN Kurauchi, Masahiko, Kanagawa, JAPAN
Miyazawa, Yuki, Kanagawa, JAPAN
Sato, Hiroyuki, Kanagawa, JAPAN
PI US 2004192553 A1 20040930
AI US 2004-808536 A1 20040325 (10)
RLI Continuation of Ser. No. WO 2002-JP9184, filed on 10 Sep 2002, UNKNOWN
PRAI JP 2001-297011 20010927
DT Utility
FS APPLICATION
LREP AJINOMOTO CORPORATE SERVICES, LLC, INTELLECTUAL PROPERTY DEPARTMENT, 1120 CONNECTICUT AVE., N.W., WASHINGTON, DC, 20036
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN DUPLICATE DUPLICATE 1
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
ABEN A novel substance inosine/L-arginine salt and a cell activator or a plant growth
promoter prepared by dissolving the salt in water. These agents are inosine preparations
which can be distributed as a solid product and quickly dissolved before using.
ABFR La presente invention concerne une nouvelle substance, un sel d'inosine/de
L-arginine et un activateur cellulaire ou promoteur de croissance vegetale
prepare par dissolution du sel dans l'eau. Les agents sont des preparations d'inosine qui peuvent etre distribuees
sous la forme d'un produit solide et dissoutes rapidement avant utilisation.
AN 2003029265 PCTFULL ED 20030416 EW 200315
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
IN KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP]
PA AJINOMOTO CO., INC., 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JP [JP, JP], for all designates States except US;
KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only
AG SHIMOKOSHI, Masao, 9th Fl., Taka-ai Bldg., 15-2, Nihombashi 3-chome,

Chuo-ku, Tokyo 103-0027, JP
LAF Japanese
LA Japanese
DT Patent
PI WO 2003029265 A1 20030410
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-JP9184 A 20020910
PRAI JP 2001-2001-297011 20010927

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
AB The L-arginine salt of inosine (I) enhances the solubility of inosine and enables easy translocation of the inosine. The L-arginine and inosine form salt at 1:1 ratio. I is useful for stimulation of cell activity and promotion of plant growth such as rooting. Preparation of I and promotion of growth of bent grass with I were shown.
AN 2003:257896 CAPLUS
DN 138:250168
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
IN Kurauchi, Masahiko; Miyazawa, Yoshinori; Sato, Hiroyuki
PA Ajinomoto Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003096090	A2	20030403	JP 2001-297011	20010927
	WO 2003029265	A1	20030410	WO 2002-JP9184	20020910
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1547585	A	20041117	CN 2002-816591	20020910
	US 2004192553	A1	20040930	US 2004-808536	20040325
PRAI	JP 2001-297011	A	20010927		
	WO 2002-JP9184	A1	20020910		

L13 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 3
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.
AB Field-jump techniques provide a very useful method for the investigation of protein-nucleic acid interactions. Electric field pulses induce the dissociation of nucleotide-peptide complexes by a dissociation field effect. Amplitudes and time constants of this effect can be used to

determine both thermodynamic and kinetic parameters. This method, as well as conventional UV absorbance and circular dichroism titrations, is applied to study the interaction of various combinations of the oligonucleotides (A)4, (A)5, (A)6, (dA)6, (I)6, (U)6 and (C)6 (all lacking terminal phosphates) with oligopeptides (Lys)2, (Lys)3, (Arg)2, (Arg)3, Lys-Gly-Lys, Lys-Phe-Lys, Lys-Tyr-Lys and Lys-Trp-Lys. As demonstrated by chain length dependences the affinity increases with an increasing number of negative charges on the oligonucleotide and of positive charges on the oligopeptide. In addition to these electrostatic effects there are some more specific interactions, demonstrated by the fact that the stability constant for the interaction of (I)6 with (Arg)3 is higher by a factor of 4 than the corresponding constant obtained with (Lys)3. This effect is attributed to H-bonding between the guanidino group of arginine and the hypoxanthine base. The data obtained with peptides containing aromatic residues reveal only relatively weak interactions of these residues with the bases of the oligonucleotides. The dynamics of the oligonucleotide-oligopeptide interactions are characterized by very high rates. The complex formation is a diffusion-controlled reaction with some acceleration due to electrostatic attraction effects. The lifetime of the complexes investigated is in the microsecond time range.

AN 1978:231393 BIOSIS
DN PREV197866043890; BA66:43890
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.
AU PORSCHKE D [Reprint author]
CS MAX-PLACK-INST BIOPHYS CHEM, POSTFACH 968, D-3400 GOETTINGEN-NIKOLAUSBERG, W GER
SO European Journal of Biochemistry, (1978) Vol. 86, No. 1, pp. 291-300. CODEN: EJBCAI. ISSN: 0014-2956.
DT Article
FS BA
LA ENGLISH

=> s arginine/ab and inosine/ab
L14 223 ARGININE/AB AND INOSINE/AB

=> s L14 and solubility/ab
L15 2 L14 AND SOLUBILITY/AB

=> d L14 1-2 ti abs bib

L14 ANSWER 1 OF 223 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA.
AB Bacterial tRNA adenosine deaminases (TadAs) catalyze the hydrolytic deamination of adenosine to inosine at the wobble position of tRNA(Arg2), a process that enables this single tRNA to recognize three different arginine codons in mRNA. In addition, inosine is also introduced at the wobble position of multiple eukaryotic tRNAs. The genes encoding these deaminases are essential in bacteria and yeast, demonstrating the importance of their biological activity. Here we report the crystallization and structure determination to 2.0 angstrom of Staphylococcus aureus TadA bound to the anticodon stem-loop of tRNAArg2 bearing nebularine, a non-hydrolyzable adenosine analog, at the wobble position. The cocrystal structure reveals the basis for both sequence and structure specificity in the interactions of TadA with RNA, and it additionally provides insight into the active site architecture that promotes efficient hydrolytic deamination.
AN 2006:272371 BIOSIS
DN PREV200600276598
TI Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA.

AU Losey, Heather C.; Ruthenburg, Alexander J.; Verdine, Gregory L. [Reprint Author]
CS Harvard Univ, Dept Chem and Biol Chem, Cambridge, MA 02138 USA
gregory_verdine@harvard.edu
SO Nature Structural & Molecular Biology, (FEB 2006) Vol. 13, No. 2, pp. 153-159.
ISSN: 1545-9985.
DT Article
LA English
ED Entered STN: 17 May 2006
Last Updated on STN: 17 May 2006

L14 ANSWER 2 OF 223 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Nitrogen oxide blockade does not aggravate the endothelin-1-induced myocardial ischemia and release of purine metabolites from the dog heart.
AB Increased intrapericardial levels of endothelin-1 (ET-1) induce myocardial ischemia and concomitant release of the purine metabolites adenosine (ADO), inosine (INO) and hypoxanthine (HXA) into the pericardial fluid. However, the potential modulatory role of nitrogen monoxide in compensating the ET-1-induced ischemic stress is not fully elucidated. The pericardial elevations of purine metabolite concentrations in the pericardial fluid after ET-1 administration (150 pmol/kg intrapericardially) were measured in the in situ dog heart with (n = 6) or without (n = 5) systemic nitrogen monoxide synthase blockade (30 mg/kg (G)-nitro-L-arginine methyl ester, followed by 6 mg/min intravenously). After control sampling, three consecutive pericardial infusate samples (ET1, ET2, ET3) were obtained for purine metabolite determinations (high-performance liquid chromatography-ultraviolet). It was found that intrapericardial ET-1 elevated the pericardial purine metabolite concentrations significantly in both groups. No significant differences were detected between the control and (G)-nitro-L-arginine methyl ester-treated groups in ischemic changes of pericardial ADOmax (+3.27 +/- 1.13 muM versus +1.84 +/- 0.56 muM), INOmax (+15.21 +/- 2.3 muM versus +12.09 +/- 4.04 muM and HXAmax (+16.34 +/- 2.98 muM versus +17.09 +/- 5.22muM levels and in the maximal ST elevations (0.43 +/- 0.05 mV versus 0.61 +/- 0.08 mV). The hemodynamic variables did not change with ET-1 administration. In conclusion, systemic nitrogen monoxide synthase blockade does not aggravate the ET-1-induced acute myocardial ischemia and the release of purine metabolites, suggesting that endogenous nitrogen monoxide is not a supplementary factor to purine metabolites in this type of coronary adaptive responses.
AN 2005:138870 BIOSIS
DN PREV200500137241
TI Nitrogen oxide blockade does not aggravate the endothelin-1-induced myocardial ischemia and release of purine metabolites from the dog heart.
AU Zima, Endre [Reprint Author]; Kekesi, Violetta; Nagy, Andrea; Barat, Erzsehet; Huszar, Eva; Toma, Ildiko; Merkely, Bela; Juhasz-Nagy, Alexander
CS Dept Cardiovasc Surg, Semmelweis Univ Med, Varosmajor U 68, H-1122, Budapest, Hungary
endzim@primposta.hu
SO Journal of Cardiovascular Pharmacology, (November 2004) Vol. 44, No. Suppl. 1, pp. S313-S317. print.
CODEN: JCPCDT. ISSN: 0160-2446.
DT Article
LA English
ED Entered STN: 6 Apr 2005
Last Updated on STN: 6 Apr 2005

=> s L14 and complex/ab
L16 16 L14 AND COMPLEX/AB

=> dup rem L16
PROCESSING COMPLETED FOR L16

L17 5 DUP REM L16 (11 DUPLICATES REMOVED)

=> d L17 1-5 ti

L17 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
TI Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site.

L17 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 2
TI Serine 948 and Threonine 1042 are crucial residues for allosteric regulation of Escherichia coli carbamoylphosphate synthetase and illustrate coupling effects of activation and inhibition pathways.

L17 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 3
TI Crystal structure of Tritrichomonas foetus inosine-5'-monophosphate dehydrogenase and the enzyme-product complex.

L17 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 4
TI Tritrichomonas foetus: A strategy for structure-based inhibitor design of a protozoan inosine-5'-monophosphate dehydrogenase.

L17 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 5
TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES AND THEIR COMPONENTS.

=> d l17 5 ti abs bib

L17 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 5
TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES AND THEIR COMPONENTS.
AB PMR was used to investigate the specificity of interaction of arginine and lysine with [calf thymus] DNA and the polynucleotides poly (G), poly (I), poly (A), poly (C), poly (U) and an interaction of histones F1 and F2a1 with poly (I). In all cases complexes of arginine are more stable and more specific than those of lysine. The interaction of arginine with polynucleotides decreases in the following order: G > I > C ≥ A > U. Changes in the solubility of the purine nucleosides adenosine, guanosine and inosine and the pyrimidine bases thymine and cytosine in the presence of glycine, arginine and lysine were studied. The apparent association constants for the complex formation were calculated. In addition to specific H-bonds between the arginine guanidine group and the 0-6, N-7 of guanine and inosine or the 0-2, N-3 of cytosine, the formation of specific H-bonds probably takes place between the carboxyl group of the amino acid and the H-N1, H-N2 guanine groups.
AN 1976:170387 BIOSIS
DN PREV197662000387; BA62:387
TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES AND THEIR COMPONENTS.
AU BRUSKOV V I; BUSHUEV V N
SO Bioorganicheskaya Khimiya, (1975) Vol. 1, No. 11, pp. 1606-1615. CODEN: BIKHD7. ISSN: 0132-3423.
DT Article
FS BA
LA Unavailable

=> s L14 and salt/ab

```
L18          12 L14 AND SALT/AB

=> dup rem L18
PROCESSING COMPLETED FOR L18
L19          10 DUP REM L18 (2 DUPLICATES REMOVED)

=> d L19 1-10 ti

L19  ANSWER 1 OF 10  USPATFULL on STN
TI     Inosine L-Arginine salt and uses thereof

L19    ANSWER 2 OF 10    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR   SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L19  ANSWER 3 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Inosine arginine salt for cell activity-stimulating agent and plant growth
     promoter

L19  ANSWER 4 OF 10  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
     DUPLICATE 1
TI   Mast cell amines and inosine-induced vasoconstriction in the rat hind
     limb.

L19  ANSWER 5 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Changes in nutritional components of Toha-jeot (salt-fermented Toha
     shrimp) during fermentation

L19  ANSWER 6 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   The taste compounds of fermented squid, Loligo kobiensis

L19  ANSWER 7 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Stabilizing α-lipoic acid in pharmaceutical solutions

L19  ANSWER 8 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Employment of microinjection techniques and large nerve and muscle fibers
     in the study of active transport and muscular contraction

L19  ANSWER 9 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   The effects of injecting energy-rich phosphate compounds on the active
     transport of ions in the giant axons of Loligo

L19  ANSWER 10 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Amino acids and growth factors in chemically defined medium for Drosophila


=> d l19 1 2 3 4 7 ti abs bib

L19  ANSWER 1 OF 10  USPATFULL on STN
TI     Inosine L-Arginine salt and uses thereof
AB     The present invention discloses an inosine. L-arginine
       salt, compositions containing the salt, and methods of
       using the salt and said compositions for cell activation
       and/or plant growth promotion. The salt can be stored and
       transported as a solid and dissolves quickly and efficiently when
       needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2004:247954  USPATFULL
TI     Inosine L-Arginine salt and uses thereof
IN     Kurauchi, Masahiko, Kanagawa, JAPAN
       Miyazawa, Yuki, Kanagawa, JAPAN
       Sato, Hiroyuki, Kanagawa, JAPAN
PI     US 2004192553      A1   20040930
AI     US 2004-808536     A1   20040325 (10)
```

RLI Continuation of Ser. No. WO 2002-JP9184, filed on 10 Sep 2002, UNKNOWN
PRAI JP 2001-297011 20010927
DT Utility
FS APPLICATION
LREP AJINOMOTO CORPORATE SERVICES, LLC, INTELLECTUAL PROPERTY DEPARTMENT, 1120 CONNECTICUT AVE., N.W., WASHINGTON, DC, 20036
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 10 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
ABEN A novel substance inosine/L-arginine salt and a cell activator or a plant growth promoter prepared by dissolving the salt in water. These agents are inosine preparations which can be distributed as a solid product and quickly dissolved before using.
ABFR La presente invention concerne une nouvelle substance, un sel d' inosine/de L-arginine et un activateur cellulaire ou promoteur de croissance vegetale prepare par dissolution du sel dans l'eau. Les agents sont des preparations d'inosine qui peuvent etre distribuees sous la forme d'un produit solide et dissoutes rapidement avant utilisation.
AN 2003029265 PCTFULL ED 20030416 EW 200315
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
IN KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP]
PA AJINOMOTO CO., INC., 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JP [JP, JP], for all designates States except US;
KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only
AG SHIMOKOSHI, Masao, 9th Fl., Taka-ai Bldg., 15-2, Nihombashi 3-chome, Chuo-ku, Tokyo 103-0027, JP
LAF Japanese
LA Japanese
DT Patent
PI WO 2003029265 A1 20030410
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-JP9184 A 20020910
PRAI JP 2001-2001-297011 20010927

L19 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
AB The L-arginine salt of inosine (I) enhances the solubility of inosine and enables easy translocation of the inosine. The L-arginine and inosine form salt at 1:1 ratio. I is useful for stimulation of cell activity and promotion of plant growth such as rooting. Preparation of I and promotion of growth of bent grass with I were shown.
AN 2003:257896 CAPLUS
DN 138:250168
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
IN Kurauchi, Masahiko; Miyazawa, Yoshinori; Sato, Hiroyuki
PA Ajinomoto Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003096090	A2	20030403	JP 2001-297011	20010927
WO 2003029265	A1	20030410	WO 2002-JP9184	20020910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1547585	A	20041117	CN 2002-816591	20020910
US 2004192553	A1	20040930	US 2004-808536	20040325
PRAI JP 2001-297011	A	20010927		
WO 2002-JP9184	A1	20020910		

L19 ANSWER 4 OF 10 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
TI Mast cell amines and inosine-induced vasoconstriction in the rat hind limb.
AB Under certain circumstances injected inosine causes a net vasoconstrictive effect on the arterioles, which has been attributed to 5-hydroxytryptamine (5HT) released in response to adenosine type 3 (A-3) receptor stimulation of mast cells residing in the adventitia. We have sought further evidence for this hypothesis using blood vessels of the rat hind limb perfused in vitro at constant rate with a gelatin-containing physiological salt solution. Injection of inosine (2.7mg) caused a rise in perfusion pressure, which was only slightly increased by inclusion of N-nitro-L-arginine methyl ester (100 mu-M) in the perfusate. inclusion in the perfusate of cyproheptadine (1 mu-M), compound 48/80 (1 mu-g/ml), 8-phenyltheophylline (1 mu-M) or 8-cyclopentyl-1,3 dipropylxanthine (0.1 mu-M) greatly reduced the pressor response to inosine. The pressor effect of injected 5HT (400 mu-g) was abolished by pre-treatment with cyproheptadine, but not by pre-treatment with compound 48/80. These results suggest that the net pressor response to injected inosine was mainly the result of an A1 receptor-mediated release of 5HT, most probably from mast cells. No evidence was found for an involvement of A-3 receptor stimulation.
AN 1997:321098 BIOSIS
DN PREV199799611586
TI Mast cell amines and inosine-induced vasoconstriction in the rat hind limb.

AU Northover, A. M. [Reprint author]; Northover, B. J.
CS Dep. Pharmaceutical Sci., Sch. Applied Sci., De Montfort Univ., Leicester LE1 9BH, UK
SO Mediators of Inflammation, (1997) Vol. 6, No. 2, pp. 141-145.
ISSN: 0962-9351.
DT Article
LA English
ED Entered STN: 26 Jul 1997
Last Updated on STN: 26 Jul 1997

L19 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Stabilizing α-lipoic acid in pharmaceutical solutions
AB The light stability of α-lipoic acid in pharmaceutical solns. was increased by the addition of 70 mg/l. vitamin B6 or a molar equivalent amount of a vitamin B6 salt or H3PO4 ester. For example, a stabilized solution contained KH2PO4 1.36, Na2SO4.10H2O 0.64, NaOAc.3H2O 1.36, Na2CO3 1.64, L-malic acid 2.5, sorbitol 50.0, xylitol 50.0, choline chloride 4.0, methionine 2.0, arginine 3.5, glycine 1.0, orotic acid 0.2, inosine 0.05, adenine 0.01, α-lipoic acid 0.20, nicotinic acid amide 0.20, pyridioxine-HCl 0.20, and inositol 0.20 g/l. in 0.5 ml EtOH and 500 ml H2O.
AN 1972:17803 CAPLUS
DN 76:17803
TI Stabilizing α-lipoic acid in pharmaceutical solutions
IN Roessler, Richard; Mader, Helmut
PA Pfrimmer, J., und Co.
SO Ger., 4 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1617740	A	19711104	DE 1967-P43060	19670925
PRAI	DE 1967-P43060	A	19670925		

=> d his

(FILE 'HOME' ENTERED AT 13:21:40 ON 12 JUL 2006)

FILE 'REGISTRY' ENTERED AT 13:21:53 ON 12 JUL 2006
L1 1 S INOSINE/CN
L2 2 S ARGININE/CN
EXP INOSINE
EXP INOSINE/CN
SEL L1
SEL L2

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:23:09 ON 12 JUL 2006
SEA (E1-E27) AND (E28-E44)

2	FILE ADISCTI
5	FILE AGRICOLA
5	FILE ANABSTR
29	FILE AQUASCI
3	FILE BIOENG
88	FILE BIOSIS
17	FILE BIOTECHABS
17	FILE BIOTECHDS
24	FILE BIOTECHNO

```
              20   FILE CABA
             396   FILE CAPLUS
               2   FILE CEABA-VTB
               2   FILE CROPU
               2   FILE DDFB
               9   FILE DDFU
              39   FILE DGENE
               8   FILE DISSABS
               2   FILE DRUGB
               5   FILE DRUGMONOG2
              10   FILE DRUGU
              84   FILE EMBASE
              34   FILE ESBIOBASE
               1   FILE FROSTI
              30   FILE FSTA
             308   FILE GENBANK
              63   FILE IFIPAT
              11   FILE JICST-EPLUS
              26   FILE LIFESCI
              82   FILE MEDLINE
              11   FILE OCEAN
              23   FILE PASCAL
               1   FILE PHIN
               4   FILE PROMT
               1   FILE RDISCLOSURE
              71   FILE SCISEARCH
              81   FILE TOXCENTER
            7417   FILE USPATFULL
             659   FILE USPAT2
              54   FILE WPIDS
              54   FILE WPINDEX
               2   FILE DPCI
             527   FILE EPFULL
              93   FILE FRFULL
              53   FILE GBFULL
               7   FILE INPADOC
               2   FILE JAPIO
               3   FILE PATDPAFULL
            6553   FILE PCTFULL
               1   FILE PIRA
L3              QUE ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI O
                ---------

     FILE 'BIOSIS, EMBASE, MEDLINE, USPATFULL, PCTFULL, EPFULL, CAPLUS'
     ENTERED AT 13:36:40 ON 12 JUL 2006
L4         15147 S (E1-E27) AND (E28-E44)

     FILE 'REGISTRY' ENTERED AT 13:38:34 ON 12 JUL 2006
                EXP ARGININE/CN
                EXP ARGININE INOSINATE/CN

     FILE 'BIOSIS, EMBASE, MEDLINE, USPATFULL, PCTFULL, EPFULL, CAPLUS'
     ENTERED AT 13:39:17 ON 12 JUL 2006
L5          9456 S L4 AND SOLUBILITY
L6             5 S L5 AND AGRININE
L7             0 S L5 AND (ARGININE(W)INOSINATE)
L8             0 S L5 AND (INOSINE(W)ARGINATE)
L9          8073 S L5 AND SALT
L10         1830 S L5 NOT PY>2000
L11        57015 S ARGININE/TI
L12           12 S ARGININE/TI AND INOSINE/TI
L13            5 DUP REM L12 (7 DUPLICATES REMOVED)
L14          223 S ARGININE/AB AND INOSINE/AB
L15            2 S L14 AND SOLUBILITY/AB
L16           16 S L14 AND COMPLEX/AB
```

```
L17             5 DUP REM L16 (11 DUPLICATES REMOVED)
L18            12 S L14 AND SALT/AB
L19            10 DUP REM L18 (2 DUPLICATES REMOVED)

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                75.64     329.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.25      -2.25

STN INTERNATIONAL LOGOFF AT 13:47:28 ON 12 JUL 2006
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> exp inosine/cn
E1            1     INOSINATE NUCLEOSIDASE/CN
E2            1     INOSINATE PYROPHOSPHORYLASE/CN
E3            1 --> INOSINE/CN
E4            1     INOSINE (5'-), 5'-(PENTAHYDROGEN TETRAPHOSPHATE)/CN
E5            1     INOSINE 2',3',5'-TRINITRATE/CN
E6            1     INOSINE 2',5'-DIPHOSPHATE/CN
E7            1     INOSINE 2'-MONOPHOSPHATE/CN
E8            1     INOSINE 3',5'-CYCLIC MONOPHOSPHATE/CN
E9            1     INOSINE 3',5'-DIPHOSPHATE/CN
E10           1     INOSINE 3',5'-DIPHOSPHATE, 5'-ANHYDRIDE WITH H2SO4/CN
E11           1     INOSINE 3',5'-MONOPHOSPHATE/CN
E12           1     INOSINE 3'-(HEXAHYDROGEN PENTAPHOSPHATE), 3'.FWDARW.5'-ESTER
                     WITH 2',3'-O-(1-ETHOXY-2-(((PHENYLMETHOXY)CARBONYL)AMINO)PR
                    OPYLIDENE)INOSINE/CN

=> exp arginine/cn
E1            1     ARGININANILIDE, NA,NΩ,NΩ-TRIS(PHENYLCARBAM
                    OYL)-, L-/CN
E2            1     ARGININANILIDE, N2-BENZOYL-/CN
E3            2 --> ARGININE/CN
E4            1     ARGININE B-NAPHTHYLAMIDE/CN
E5            1     ARGININE 2,2,2-TRICHLOROETHYL ESTER/CN
E6            1     ARGININE 2,3-AMINOMUTASE/CN
E7            1     ARGININE 2,3-AMINOMUTASE (STREPTOMYCES GRISEOCHROMOGENES GEN
                    E BLSG)/CN
E8            1     ARGININE 2-MONOOXYGENASE/CN
E9            1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN
E10           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN
E11           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI STRAIN O157:H7 GENE ECS0943)/CN
E12           1     ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
                    SCHERICHIA COLI STRAIN O157:H7 GENE ECS0946)/CN

=> exp isoprinosine
E1            1     ISOPRINOSIN/BI
E2            1     ISOPRINOSINA/BI
E3            1 --> ISOPRINOSINE/BI
E4            1     ISOPRINTZIANIC/BI
E5            5     ISOPRISTIMERIN/BI
E6           33     ISOPRO/BI
E7            1     ISOPROBENPHOS/BI
```

```
E8            1      ISOPROBO/BI
E9            1      ISOPROBOTRI/BI
E10           1      ISOPROBOTRIAN/BI
E11           5      ISOPROBOTRYAN/BI
E12          16      ISOPROCARB/BI

=> s inosine/cn
L1            1 INOSINE/CN

=> sel L1
E1 THROUGH E27 ASSIGNED

=> file medline biosis embase scisearch uspatfull pctfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 6.41       6.62

FILE 'MEDLINE' ENTERED AT 16:38:30 ON 12 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:38:30 ON 12 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 16:38:30 ON 12 JUL 2006
COPYRIGHT (C) 2006 Univentio

=> s solubility(6a)(E1-E27)
L2           19 SOLUBILITY(6A)((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOS
                IDE"/BI OR "HYPOXANTHINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-
              D-RIBOFURANOSIDE"/BI OR "HYPOXANTHINE, 9-B-D-RIBOFURANOSYL-"
              /BI OR HYPOXANTHOSINE/BI OR INO/BI OR INOSIE/BI OR INOSINE/BI OR
              "NSC 20262"/BI OR OXIAMIN/BI OR PANHOLIC-L/BI OR RIBONOSINE/BI
              OR SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIHYDRO-9-B-D-RIBOFU
              RANOSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 132953-54-9/BI OR
              28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58-63-9/BI OR
              "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR
              691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOX
              ANTHINE/BI))

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3            16 DUP REM L2 (3 DUPLICATES REMOVED)

=> d L3 1-16 ti

L3   ANSWER 1 OF 16  USPATFULL on STN
TI     Inosine L-Arginine salt and uses thereof

L3   ANSWER 2 OF 16  USPATFULL on STN
TI     Buoyant polymer particles for delivery of therapeutic agents to the
       central nervous system

L3     ANSWER 3 OF 16    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   BUOYANT POLYMER PARTICLES FOR DELIVERY OF THERAPEUTIC AGENTS TO THE
       CENTRAL NERVOUS SYSTEM
TIFR   ARTICLES POLYMERES FLOTTANTS POUR L'ADMINISTRATION D'AGENTS
       THERAPEUTIQUES AU SYSTEME NERVEUX CENTRAL
```

L3 ANSWER 4 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN WATER-SWELLABLE POLYMERS
TIFR POLYMERES GONFLABLES DANS L'EAU

L3 ANSWER 5 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of colon cancer

L3 ANSWER 6 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer

L3 ANSWER 7 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of colon cancer

L3 ANSWER 8 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of ovarian cancer

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent

L3 ANSWER 11 OF 16 MEDLINE on STN DUPLICATE 1
TI Synthesis of RNA containing inosine: analysis of the sequence requirements for the 5' splice site of the Tetrahymena group I intron.

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Purification of inosine from guanosine

L3 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET D'UTILISATION

L3 ANSWER 14 OF 16 USPATFULL on STN
TI Ultrafiltration of fermentation broth containing nucleosides to separate inosine and guanosine from the broth

L3 ANSWER 15 OF 16 USPATFULL on STN
TI INOSINE DERIVATIVES

L3 ANSWER 16 OF 16 USPATFULL on STN
TI INOSINE DERIVATIVES

=> d L3 5 6 7 8 9 10 12 13 15 16 ti abs bib

L3 ANSWER 5 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of colon cancer
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:237907 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of colon cancer
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002132237 A1 20020919
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent
AB Herein are disclosed, a plant-root growth promoting agent, which comprises inosine as the effective ingredient, as well as a method for promoting plant root growth, which comprise applying such plant-root growth promoting agent to the soil or, in the case of hydroponics, to the hydroponic water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:158224 USPATFULL
TI Plant-root growth promoting agent
IN Murayama, Akira, Morotomi-machi, Japan
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
PI US 6291398 B1 20010918
AI US 1999-469298 19991222 (9)
RLI Continuation of Ser. No. US 1997-962688, filed on 3 Nov 1997, now patented, Pat. No. US 6143695
PRAI JP 1996-298550 19961111
JP 1997-16006 19970314
DT Utility
FS GRANTED
EXNAM Primary Examiner: Clardy, S. Mark
LREP Oblon, Spivak. McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent
AB Herein are disclosed, a plant-root growth promoting agent, which comprises inosine as the effective ingredient, as well as a method for promoting plant root growth, which comprise applying such plant-root growth promoting agent to the soil or, in the case of hydroponics, to the hydroponic water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:150115 USPATFULL
TI Plant-root growth promoting agent
IN Murayama, Akira, Morotomi-machi, Japan
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
PI US 6143695 20001107
AI US 1997-962688 19971103 (8)
PRAI JP 1996-298550 19961111
JP 1997-61006 19970314
DT Utility
FS Granted
EXNAM Primary Examiner: Clardy, S. Mark
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Purification of inosine from guanosine
AB An industrially advantageous process for producing an inosine-guanosine mixture having a higher weight ratio of guanosine/inosine than a starting mixture of nucleoside crystals and inosine subtantially free of guanosine from which comprises adjusting an aqueous fluid containing 10 to 30% by weight/volume of a nucleoside mixture to a pH of 9.1 to 9.5,

wherein the total amount of inosine and guanosine is more than 95% by weight based on dry matters and the weight ratio of guanosine/inosine is 0.5 to 1, separating the resultant solids and then crystallizing inosine from the resulting solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 90:73582 USPATFULL
TI Purification of inosine from guanosine
IN Fujinawa, Shohei, Himeji, Japan
Sakamoto, Yoshinori, Takasago, Japan
Iizuka, Harumasa, Kakogawa, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4958017 19900918
AI US 1988-283805 19881213 (7)
PRAI JP 1987-320743 19871217
DT Utility
FS Granted
EXNAM Primary Examiner: Rollins, John W.; Assistant Examiner: Kunz, Gary L.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET D'UTILISATION
ABEN Novel solute and crystal polymorphs of inosine. Also, a method of preparing a crystal polymorph of inosine comprising: providing a solvent; adding to the solvent at least about three grams of inosine per about 100 milliliters of the solvent; heating the solvent and the inosine at a predetermined rate to a temperature sufficient to cause the inosine to go into solution and to overcome the energy barriers which prevent the conversion of the inosine to another polymorphic configuration; cooling the solution at a predetermined rate for a predetermined period of time; and precipitating the crystal polymorph of inosine. The cooling step may comprise a single step or several steps. Freezing and lyophilization may be substituted for the precipitation step to produce the crystal polymorph. The invention further comprises a method of preparing solute polymorphs of inosine comprising dissolving inosine crystal polymorphs in a solvent. The solute polymorphs of the invention may also be prepared using the method described above for the preparation of crystal polymorphs, except that the step of precipitating and the steps of freezing and lyophilizing are not performed. Finally, according to the invention, there are provided anti-inflammatory compositions comprising an amount of a solute or crystal polymorph of inosine effective to reduce an inflammatory response in an animal and methods of reducing an inflammatory response in an animal comprising administering these compositions to the animal.
ABFR Nouvelles formes polymorphes de l'inosine, solutes et cristaux. Procede de preparation d'un cristal polymorphe de l'inosine consistant a: utiliser un solvant; a ajouter au solvant au moins 3 grammes d'inosine pour 100 ml de solvant environ; a chauffer le solvant

et l'inosine, selon une
vitesse predeterminee, pour atteindre une temperature suffisante pour provoquer la mise en solution
de l'inosine et pour vaincre les barrieres energetiques qui empechent la conversion de l'inosine en
une autre configuration polymorphe; a refroidir la solution selon une vitesse predeterminee pendant
une periode predeterminee, et a precipiter le cristal d'inosine polymorphe. Le refroidissement peut
s'effectuer en une ou plusieurs etapes. On peut remplacer la precipitation par la lyophilisation
pour produire le cristal polymorphe. L'invention se rapporte egalement a une procede de prepartion
de solutes polymorphes de l'inosine consistant a dissoudre les cristaux polymorphes d'inosine dans
un solvant. On peut egalent preparer des solutes polymorphes selon l'invention en utilisant le
procede decrit precedemment pour la preparation de cristaux polymorphes, seules les etapes de
precipitation et de lyophilisation etant omises. Compositions anti-inflammatoires comprenant une
quantite d'un solute ou d'un cristal polymorphe d'inosine efficace pour attenuer la reponse
inflammatoire d'un animal, et procedes de reduction de la reponse inflammatoire d'un animal
consistant a administrer ces compositions a l'animal.

AN 1988009335 PCTFULL ED 20020507
TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET D'UTILISATION
IN GORDON, Paul
PA GORDON, Paul
LA English
DT Patent
PI WO 8809335 A1 19881201
DS W: AT AU BB BE BG BJ BR CF CG CH CM DE DK FI FR GA GB HU IT
JP KP KR LK LU MC MG ML MR MW NL NO RO SD SE SN SU TD TG
AI WO 1988-US1468 A 19880510
PRAI US 1987-54,353 19870526

L3 ANSWER 15 OF 16 USPATFULL on STN
TI INOSINE DERIVATIVES
AB Complexes are formed in inosine and aminoalcohols of the formula ##SPC1##

Where R.sub.1 and R.sub.2 are lower alkyl and n is an integer of 2 to 4. The complexes have pharmacological activity including the ability to restore deteriorated learning and memory behavior. The preferred aminoalcohol is dimethylamino isopropanol. The preferred ratio of inosine to aminoalcohol is 1:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 74:62050 USPATFULL
TI INOSINE DERIVATIVES
IN Gordon, Paul, Chicago, IL, United States
PA Newport Pharmaceuticals, Inc., Newport Beach, CA, United States (U.S. corporation)
PI US 3857940 19741231
AI US 1972-311732 19721207 (5)
RLI Division of Ser. No. US 1971-145929, filed on 21 May 1971, now Defensive Publication No. which is a division of Ser. No. US 1969-853864, filed on 28 Aug 1969, now patented, Pat. No. US 3646007, issued on 29 Feb 1972
DT Utility
FS Granted
EXNAM Primary Examiner: Roberts, Elbert L.

```
LREP   Cushman, Darby & Cushman
CLMN   Number of Claims: 9
ECL    Exemplary Claim: 1
DRWN   3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3   ANSWER 16 OF 16  USPATFULL on STN
TI     INOSINE DERIVATIVES
AB     Complexes are formed in inosine and amino-alcohols of the formula
       ##SPC1##

       Where R.sub.1 and R.sub.2 are lower alkyl and n is an integer of 2 to 4.
       The complexes having pharmacological activity including the ability to
       restore deteriorated learning and memory behavior. The preferred
       aminoalcohol is dimethylamino isopropanol. The preferred ratio of
       inosine to aminoalcohol is 1:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     73:16662  USPATFULL
TI     INOSINE DERIVATIVES
IN     Gordon, Paul, Chicago, IL, United States
PA     Newport Pharmaceuticals, Inc., Newport, CA, United States (U.S.
       corporation)
PI     US 3728450              19730417
AI     US 1971-145929          19710521 (5)
RLI    Division of Ser. No. US 1969-853864, filed on 28 Aug 1969, now patented,
       Pat. No. US 3645007, issued on 29 Feb 1972
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Rose, Shep K.
LREP   Cushman, Darby & Cushman
CLMN   Number of Claims: 9
DRWN   3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s inosine-arginine
L4            0 INOSINE-ARGININE

=> s inosine(6a)arginine
L5           70 INOSINE(6A) ARGININE

=> s inosine(4a)arginine
L6           48 INOSINE(4A) ARGININE

=> s L6 not py>2001
L7           30 L6 NOT PY>2001

=> dup rem L7
PROCESSING COMPLETED FOR L7
L8            22 DUP REM L7 (8 DUPLICATES REMOVED)

=> d L8 1-22 ti

L8     ANSWER 1 OF 22    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR   LUTTE CONTRE LES BACTERIES SPORULEES

L8   ANSWER 2 OF 22  USPATFULL on STN
TI     Method for producing of phthalocyanine compound

L8   ANSWER 3 OF 22  USPATFULL on STN
TI     Cloning and expression of human GMP synthetase, its use in screening for
```

inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 4 OF 22 USPATFULL on STN
TI Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 5 OF 22 USPATFULL on STN
TI Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 6 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
TI Feeding behavior in juvenile snook, Centropomus undecimalis. I. Individual effect of some chemical substances.

L8 ANSWER 7 OF 22 USPATFULL on STN
TI Method of making inosine monophosphate derivatives and immunopotentiating uses thereof

L8 ANSWER 8 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN IMMUNOPOTENTIATING INOSINE MONOPHOSPHATE 5'-NUCLEOTIDASE RESISTANT DERIVATIVES AND USES THEREOF
TIFR DERIVES DE L'INOSINE MONOPHOSPHATE AYANT DES PROPRIETES IMMUNOSTIMULATRICES ET RESISTANT A LA 5'-NUCLEOTIDASE, ET LEUR UTILISATION

L8 ANSWER 9 OF 22 USPATFULL on STN
TI Prophylactic and therapeutic composition for MRSA infection

L8 ANSWER 10 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CLONING AND EXPRESSION OF HUMAN GMP SYNTHETASE, ITS USE IN SCREENING FOR INHIBITORS OF HUMAN GMP SYNTHETASE AND INHIBITORS OF HUMAN GMP SYNTHETASE
TIFR CLONAGE ET EXPRESSION DE LA SYNTHETASE HUMAINE GMP ET SON EMPLOI DANS LE DEPISTAGE DES INHIBITEURS DE LA SYNTHETASE DU GUANOSINE MONOPHOSPHATE (GMP) HUMAIN, ET INHIBITEURS DE LA SYNTHETASE DU GMP HUMAIN

L8 ANSWER 11 OF 22 MEDLINE on STN DUPLICATE 2
TI Immunostimulating properties of the complexes of inosine derivatives.

L8 ANSWER 12 OF 22 USPATFULL on STN
TI Method for producing L-tryptophan by fermentation

L8 ANSWER 13 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 3
TI ERGOGENIC NUTRITIONAL SUPPLEMENTATION IN EFFORTS OF SPORTING DOGS.

L8 ANSWER 14 OF 22 USPATFULL on STN
TI Transducible composite plasmid

L8 ANSWER 15 OF 22 USPATFULL on STN
TI Plasmid

L8 ANSWER 16 OF 22 USPATFULL on STN
TI Moraxella bovis protease vaccine

L8 ANSWER 17 OF 22 USPATFULL on STN
TI Composite plasmid

L8 ANSWER 18 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI CLINICAL EVALUATION OF PHARMACOLOGICAL THERAPY ON IDIOPATHIC MALE

INFERTILITY.

L8 ANSWER 19 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI POSTMORTEM METABOLISM OF SHORT-FINNED SQUID MUSCLE ILLEX-ILLECEBROSUS.

L8 ANSWER 20 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI TASTE COMPOUNDS OF FRESH WATER FISHES 5. SENSORY EVALUATION OF TASTE COMPONENTS IN THE EXTRACT OF WILD COMMON CARP CYPRINUS-CARPIO AND KOREAN SNAKEHEAD CHANNA-ARGUS MEAT.

L8 ANSWER 21 OF 22 MEDLINE on STN DUPLICATE 4
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.

L8 ANSWER 22 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI GENETICS AND SELECTION OF ENTOMO PATHOGENIC FUNGUS BEAUVERIA-BASSIANA PART 2 VIRULENCE OF AUXOTROPHIC MUTANTS OF BEAUVERIA-BASSIANA ON DROSOPHILA-MELANOGASTER.

=> d L8 1 2 9 11 21 ti abs bib

L8 ANSWER 1 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR LUTTE CONTRE LES BACTERIES SPORULEES
ABEN Methods for controlling spores in aqueous systems, especially closed systems. These methods include contacting germinating agent with an aqueous closed system for a sufficient period of time and under non-hostile conditions so that spores capable of germinating can germinate into vegetative cells, and subjecting the germinated vegetative cells to biocidal treatment. These methods also include contacting germinating agent with the aqueous system for a sufficient period of time and under non-hostile conditions so that spores capable of germinating can germinate into vegetative cells, subjecting the germinated vegetative cells to biocidal treatment in a hostile environment; and cycling between hostile and non-hostile environments.
ABFR L'invention concerne des procedes de lutte contre les spores dans les systemes aqueux, notamment les systemes fermes. Lesdits procedes consistent a mettre un agent de germination au contact d'un systeme ferme aqueux dans des conditions non hostiles et suffisamment longtemps pour que les spores susceptibles de germer puissent germer en cellules vegetatives ; et a faire subir auxdites cellules vegetatives germees un traitement biocide. Lesdits procedes consistent egalement a mettre un agent de germination au contact du systeme aqueux dans des conditions non hostiles et suffisamment longtemps pour que les spores susceptibles de germer puissent germer en cellules vegetatives ; a faire subir auxdites cellules vegetatives germees un traitement biocide dans un environnement hostile ; et a les recycler entre des environnements hostile et non hostile.
AN 2001066471 PCTFULL ED 20020822
TIEN CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR LUTTE CONTRE LES BACTERIES SPORULEES
IN BREEN, Alexander, W.;
TAYLOR, Charles;
SMITH, Kelly, S.
PA HERCULES INCORPORATED
DT Patent
PI WO 2001066471 A2 20010913
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX

MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
NE SN TD TG

AI WO 2001-US6132 A 20010223
PRAI US 2000-09/521,422 20000308

L8 ANSWER 2 OF 22 USPATFULL on STN
TI Method for producing of phthalocyanine compound
AB A method for producing a novel phthalocyanine compound which excels in yield and purity, allows no introduction of a chlorine atom into the phthalocyanine skeleton, and possesses relatively bulky substituents is provided. This method is characterized by causing an orthophthalonitrile compound having a substituent exhibiting smaller σ.sub.p values than σ.sub.m values in the Hammett's rule to react with a metal oxide in the presence of a compound forming in the aqueous solution thereof at 25° C. an acid or conjugate acid having a dissociation index pKa (the logarithmic value of the reciprocal of the dissociation constant of the acid or conjugate acid) of not more than 7.0.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:28131 USPATFULL
TI Method for producing of phthalocyanine compound
IN Aoki, Minoru, Ibaraki, Japan
Kaieda, Osamu, Ibaraki, Japan
PA Nippon Shokubai Co., Ltd., Osaka-fu, Japan (non-U.S. corporation)
PI US 6034236 20000307
AI US 1998-92719 19980605 (9)
PRAI JP 1997-148101 19970605
JP 1998-7020 19980116
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K
LREP Fish & Richardson P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 22 USPATFULL on STN
TI Prophylactic and therapeutic composition for MRSA infection
AB The invention provides an anti-MRSA prophylactic/therapeutic composition containing as an active ingredient at least one nucleic acid component selected from among inosine, guanosine n'-monophosphate (GMP) (n'=2', 3'or 5'), uridine and thymidine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:50167 USPATFULL
TI Prophylactic and therapeutic composition for MRSA infection
IN Yamamoto, Sigeru, Naha, Japan
Yokoyama, Hiroomi, Naruto, Japan
PA Otsuka Pharmaceutical Factory, Inc., Naruto, Japan (non-U.S. corporation)
PI US 5422343 19950606
AI US 1993-26744 19930305 (8)
PRAI JP 1992-340523 19921221
DT Utility
FS Granted
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Varma, Anita
LREP Armstrong, Westerman, Hattori, McLeland and Naughton
CLMN Number of Claims: 6
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 22 MEDLINE on STN DUPLICATE 2
TI Immunostimulating properties of the complexes of inosine derivatives.
AB The effects of the complexes of inosine (Ino) analogues of isoprinosine on the immune response to sheep red blood cells (SRBC), in plaque-forming cells assay (PFC), in mice spleen, and on the Fc-dependent SRBC phagocytosis in mice peritoneal macrophages were investigated. Molar ratios of 1:3 of the complexes of inosine with N,N-dimethylaminopropanol-2-p-acetaminobenzoate (isoprinosine), and 8-thioinosine with N,N-dimethylaminopropanol-2-p-acetaminobenzoate (OSI-177), inosine with L-arginine butyrate (OSI-2655), and 8-thioinosine with L-arginine butyrate (OSI-3648) were administered. The administered doses were 0.5, 5 and 50 mg/kg body weight. The compound OSI-2655 exceeded isoprinosine in PFC stimulation and phagocytosis activation. The compound OSI-3648 exceeded isoprinosine only in PFC stimulation in the case of immunization with a suboptimal SRBC dose. OSI-3648 stimulated the immune response in PRC better than isoprinosine, OSI-177, or OSI-2655, and maintained the ability to stimulate capture, but lost the ability to stimulate destruction processes of captured SRBC. L-Arginine butyrate in the doses equivalent to its content in the complexes did not affect the number of PFC. L-Arginine butyrate was able to stimulate the processes of destruction but its stimulation degree was inferior to the compound OSI-2655.
AN 96380110 MEDLINE
DN PubMed ID: 8788123
TI Immunostimulating properties of the complexes of inosine derivatives.
AU Poluektova L; Maurinsh Y; Lidaks M; Gromova N
CS Medical Academy of Latvia, Riga.
SO International journal of immunopharmacology, (1995 Nov) Vol. 17, No. 11, pp. 941-7.
Journal code: 7904799. ISSN: 0192-0561.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199701
ED Entered STN: 28 Jan 1997
Last Updated on STN: 28 Jan 1997
Entered Medline: 16 Jan 1997

L8 ANSWER 21 OF 22 MEDLINE on STN DUPLICATE 4
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.
AN 78190631 MEDLINE
DN PubMed ID: 658044
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.
AU Porschke D
SO European journal of biochemistry / FEBS, (1978 May) Vol. 86, No. 1, pp. 291-9.
Journal code: 0107600. ISSN: 0014-2956.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197808
ED Entered STN: 14 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 14 Aug 1978

```
=> d his

     (FILE 'HOME' ENTERED AT 16:36:06 ON 12 JUL 2006)

     FILE 'REGISTRY' ENTERED AT 16:36:25 ON 12 JUL 2006
               EXP INOSINE/CN
               EXP ARGININE/CN
               EXP ISOPRINOSINE
L1              1 S INOSINE/CN
               SEL L1

     FILE 'MEDLINE, BIOSIS, EMBASE, SCISEARCH, USPATFULL, PCTFULL' ENTERED AT
     16:38:30 ON 12 JUL 2006
L2             19 S SOLUBILITY(6A)(E1-E27)
L3             16 DUP REM L2 (3 DUPLICATES REMOVED)
L4              0 S INOSINE-ARGININE
L5             70 S INOSINE(6A)ARGININE
L6             48 S INOSINE(4A)ARGININE
L7             30 S L6 NOT PY>2001
L8             22 DUP REM L7 (8 DUPLICATES REMOVED)

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               44.19      50.81

STN INTERNATIONAL LOGOFF AT 16:46:50 ON 12 JUL 2006
```